Atopic dermatitis Epidemiology

View All

dupixent-market
Can Dupixent Be A Gamechanger In The Atopic Dermatitis Treatment Landscape?

Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation, which is a major contributor to Atopic...

Find More

Atopic dermatitis market
Atopic dermatitis market: Increasing prevalence and topical treatments

Atopic dermatitis, also known as atopic eczema, is a condition that results in itchy, scaly and red skin. It is an inflammatory skin disease which is a common recurrent form of skin allergy.  Acute flare-ups of eczematous pruritic lesions mainly categorise atopic dermatitis over dry skin due to high levels ...

Find More